Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Biology
|
| gptkbp:administered_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:available_on |
lyophilized powder
|
| gptkbp:chemical_formula |
C_2_0 H_3_0 N_6 O_1_3 S_1_0
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
long-term management
|
| gptkbp:contraindication |
hypersensitivity to agalsidase alfa
|
| gptkbp:developed_by |
gptkb:Genzyme
|
| gptkbp:drug_interactions |
none known
|
| gptkbp:duration |
long-term
|
| gptkbp:financial_stability |
24 months
|
| gptkbp:financial_support |
available through manufacturer
|
| gptkbp:historical_significance |
first approved treatment for Fabry disease
|
| https://www.w3.org/2000/01/rdf-schema#label |
agalsidase alfa
|
| gptkbp:indication |
chronic kidney disease
|
| gptkbp:ingredients |
gptkb:agalsidase_alfa
|
| gptkbp:is_monitored_by |
cardiac function
renal function neurological function |
| gptkbp:marketed_as |
the brand name Fabrazyme
|
| gptkbp:mechanism_of_action |
replaces deficient enzyme
|
| gptkbp:patient_education |
important for understanding treatment
|
| gptkbp:patient_population |
adults and children
|
| gptkbp:pharmacokinetics |
dose-dependent clearance
increases enzyme activity |
| gptkbp:price |
high
|
| gptkbp:provides_guidance_on |
recommended for Fabry disease
|
| gptkbp:recommissioned |
with sterile water
|
| gptkbp:regulatory_compliance |
orphan drug designation
marketed in multiple countries |
| gptkbp:research_focus |
combination therapies
new formulations gene therapy alternatives |
| gptkbp:route_of_administration |
IV
|
| gptkbp:service_frequency |
every 2 weeks
|
| gptkbp:side_effect |
fatigue
headache nausea abdominal pain urticaria rash anaphylaxis infusion reactions arthralgia myalgia |
| gptkbp:storage |
refrigerated
|
| gptkbp:treatment |
improved quality of life
reduced symptoms slowed disease progression |
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:used_for |
gptkb:Fabry_disease
|
| gptkbp:weight |
45 k Da
|
| gptkbp:bfsParent |
gptkb:Replagal
|
| gptkbp:bfsLayer |
6
|